UK Markets closed

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.5850-0.1450 (-3.89%)
As of 01:06PM EST. Market open.
Currency in USD

Valuation measures4

We're sorry, we couldn't find any data.
Please try reloading the page.

Trading information

Stock price history

Beta (5Y monthly) 2.18
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 37.3400
52-week low 33.3700
50-day moving average 34.9739
200-day moving average 34.8284

Share statistics

Avg vol (3-month) 31.96M
Avg vol (10-day) 31.06M
Shares outstanding 5155.5M
Implied shares outstanding 6N/A
Float 8126.69M
% held by insiders 10.12%
% held by institutions 177.31%
Shares short (27 May 2021) 43.93M
Short ratio (27 May 2021) 43.99
Short % of float (27 May 2021) 4N/A
Short % of shares outstanding (27 May 2021) 42.53%
Shares short (prior month 29 Apr 2021) 44.03M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 329 Mar 2018
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-3,897.82%

Management effectiveness

Return on assets (ttm)-25.39%
Return on equity (ttm)-56.42%

Income statement

Revenue (ttm)3.63M
Revenue per share (ttm)0.02
Quarterly revenue growth (yoy)-43.00%
Gross profit (ttm)-87.61M
EBITDA -134.21M
Net income avi to common (ttm)-139.69M
Diluted EPS (ttm)-0.9290
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)317.94M
Total cash per share (mrq)2.05
Total debt (mrq)22.74M
Total debt/equity (mrq)7.36
Current ratio (mrq)11.48
Book value per share (mrq)1.99

Cash flow statement

Operating cash flow (ttm)-116.99M
Levered free cash flow (ttm)-79.47M